Eli Lilly and Company (LLY)
| Market Cap | 988.29B +36.2% |
| Revenue (ttm) | 72.25B +47.4% |
| Net Income | 25.28B +127.6% |
| EPS | 28.15 +129.1% |
| Shares Out | 891.74M |
| PE Ratio | 39.15 |
| Forward PE | 29.56 |
| Dividend | $6.92 (0.62%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 1,979,107 |
| Open | 1,117.00 |
| Previous Close | 1,102.08 |
| Day's Range | 1,079.22 - 1,122.02 |
| 52-Week Range | 623.78 - 1,182.73 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 1,218.72 (+9.97%) |
| Earnings Date | Aug 6, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,218.72, which is an increase of 9.97% from the latest price.
News
How Eli Lilly Became a $1 Trillion Company
Mounjaro and Zepbound turned Eli Lilly into a trillion-dollar pharmaceutical giant. But every blockbuster drug eventually faces competition.
Sangamo files for restructuring, plans asset sales to Lilly, Astellas
Sangamo Therapeutics (SGMO) announced that it has commenced voluntary Chapter 11 bankruptcy reorganization proceedings and entered into separate “stalking horse” asset sale agreements with Eli Lilly (...
Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe
Eli Lilly expects to launch its weight-loss pill in Europe and Britain in the second half of 2026 or early 2027, with the drugmaker targeting the out-of-pocket telehealth market as it has done in th...
Fund manager names 3 non-AI stocks to own as Intel, AMD sink amid broader tech rout
The tech sector is experiencing a sharp global sell-off today, dragging down chipmakers like Intel, AMD, Micron, and even the artificial intelligence (AI) darling – Nvidia. What's driving this weaknes...
Eli Lilly (LLY) Opens Data Center to Smaller Biotech Firms as It Chases Drug Discoveries
The pharma giant is trying to diversify its pipeline of new medicines.
Eli Lilly (LLY) Is Growing Fast at a Fair Price Even Without an AI Story
Eli Lilly ($LLY) reported strong Q1 2026 results and increased its full-year outlook, and all of this without an artificial intelligence (AI) story. Yet the stock has lagged the S&P…
Centessa announces High Court approval for acquisition by Eli Lilly
Centessa (CNTA) which entered into a definitive agreement relating to its proposed acquisition by Eli Lilly (LLY), through a wholly owned subsidiary, announced that the High Court of Justice of…
Eli Lilly price target raised to $1,135 from $1,050 at Berenberg
Berenberg analyst Kerry Holford raised the firm’s price target on Eli Lilly (LLY) to $1,135 from $1,050 and keeps a Hold rating on the shares.
Lilly declares third-quarter 2026 dividend
INDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common s...
Cantor Fitzgerald Pounds the Table on Eli Lilly Stock (LLY) Heading into Q2 Earnings Season
Sales of the company’s weight-loss pill are surging.
Doctors say that GLP-1 medications can prevent lifelong obesity and Type 2 diabetes in children—but there are some worries
Doctors are looking for better options given the growing awareness of the serious health risks tied to childhood obesity.
Eli Lilly, BioArctic enter research pact for BrainTransporter combination
BioArctic announced that the company has entered into a research and collaboration agreement with Eli Lilly (LLY) regarding a potential new treatment combining BioArctic’s BrainTransporter technology ...
Charles River to collaborate with AI/ML drug discovery platform Lilly TuneLab
The company states: “Charles River (CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (LLY). TuneLab was created to acce...
Cathie Wood’s ARK Investment buys 41K shares of Eli Lilly today
20:31 EDT Cathie Wood’s ARK Investment buys 41K shares of Eli Lilly (LLY) today
Ozempic Linked To Lower Risk Of Violence In New Study
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New J...
M&A News: Eli Lilly (LLY) Expands Into Painkiller Market with Latest Acquisition
The company has experimented with pain medicines in the past.
Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.
Eli Lilly is acquiring Austin-based 4E Therapeutics, the developer of non-addictive painkillers, for an undisclosed amount.
Eli Lilly acquires 4E Therapeutics, terms not disclosed
4E Therapeutics, an Austin-based neuroscience company developing treatments for chronic pain, announced that it has been acquired by Eli Lilly (LLY). 4E says it is developing a pipeline of orally…
Novo Nordisk Seeks China Approval for Wegovy Pill, Intensifying Rivalry with Lilly
Novo Nordisk ($NVO) is stepping up its competition with rival Eli Lilly ($LLY) in China’s oral weight loss drug market. According to a Reuters report, CEO Mike Doustdar said the…
How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade
The GLP-1 race "is not fair to call a race anymore," argues Scott Zari when comparing Eli Lilly (LLY) and Novo Nordisk (NVO), calling the former a clear winner. He explains how Eli Lilly pulled ahead ...
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
INDIANAPOLIS, June 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton t...
The Next Phase Of The Obesity Drug Race
Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others like Structure Therapeutics and Zealand Phar...
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095...
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...